Hansoh Pharmaceutical Group Company Limited (翰森製藥集團有限公司), known as Hansoh Pharma, is a leading innovation-driven pharmaceutical company headquartered in Shanghai, China. Founded in 1995, it is listed on the Hong Kong Stock Exchange (3692.HK) and operates primarily through its principal subsidiary, Jiangsu Hansoh Pharmaceutical Group Co., Ltd., based in Lianyungang, Jiangsu.
The company focuses on research, development, manufacturing, and sales of pharmaceuticals across key therapeutic areas including oncology, anti-infectives, central nervous system disorders, metabolic diseases, and autoimmune conditions. It has launched seven innovative drugs in China, such as aumolertinib mesylate (Ameile) for EGFR-mutant non-small cell lung cancer, flumatinib mesylate (Hansoh Xinfu) for chronic myelogenous leukemia, and pegmolesatide injection (Saint Luolai) for renal anemia. Hansoh maintains a robust pipeline with over 40 innovative candidates in more than 70 clinical trials.
Recognized among the top 100 global pharmaceutical companies and top 3 in China's pharmaceutical R&D pipelines, it holds national high-tech enterprise status and has partnered globally, including licensing deals with GSK, Roche, and Merck for assets like risvutatug rezetecan (HS-20093), an antibody-drug conjugate targeting B7-H3.
Also known as 江苏豪森药业集团有限公司, Jiangsu Hansoh Pharmaceutical Group Co., Ltd., Hansoh Pharma Inc., and Hansoh Pharmaceutical.
None yet. When a new project in the record names Hansoh Pharma as owner, partner or investor, it shows here.
Phase III ARTEMIS‑011 showed median PFS 5.5 vs 1.4 months (HR 0.33); safety showed high rates of grade ≥3 TRAEs with Ris‑Rez versus chemotherapy.
Phase Ib BEHOLD‑1 reports durable responses and 11.1‑month median PFS at the selected phase III dose; safety predominantly haematologic with most grade ≥3 events.
Phase Ib shows 61% ORR at 8 mg/kg with manageable safety; data supported selection of 8 mg/kg for the ongoing global phase III EMBOLD SCLC‑301.
More than 20 abstracts across lung, gynaecological and gastrointestinal cancers, including positive Ris‑Rez ES‑SCLC activity, Mo‑Rez durable responses in platinum‑resistant ovarian cancer, and Jemperli complete responses in MSI‑H rectal cancer.
Ris‑Rez extended median OS to 18.5 vs 10.3 months (HR 0.46) and showed improved PFS, response rates and fewer grade ≥3 TRAEs versus topotecan.
Core operating profit +7% and core EPS +9%; sales up, driven by Specialty Medicines and Vaccines; new R&D centre and a 3-year £1.9bn annual savings target to fund late-stage pipeline.
ARTEMIS‑011 showed significant PFS benefit versus chemotherapy in relapsed osteosarcoma after ≥2 prior therapies; OS benefit and expected safety observed; data to support Chinese submission.
FDA clears zidesamtinib for adults with advanced ROS1‑positive NSCLC after prior ROS1 inhibitor; ARROS‑1 showed 44% ORR and durable responses, including in brain metastases.
